Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase III trial of ALZ 801 in patients with Alzheimer's disease positive for e4 allele of the apolipoprotein E

Next Previous
X
Search
Trial Profile

Pivotal phase III trial of ALZ 801 in patients with Alzheimer's disease positive for e4 allele of the apolipoprotein E

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valiltramiprosate (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Alzheon

    • Most Recent Events

    • 23 Jul 2018 Data from responder analyses of this trial presented in an Alzheon Media Release.
    • 23 Jul 2018 According to an Alzheon media release, data from patient responder analyses of this trial will be presented at 2018 Alzheimers Association International Conference.
    • 02 Nov 2017 According to an Alzheon media release, data will be presented at the 10th Annual Clinical Trials on Alzheimers Disease (CTAD) congress which will be held in 1-4 Nov 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top